| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CMO And Head Of R&D
1 company
Prasad Suyash serves as a CMO And Head Of R&D at TSHA. Across recent SEC filings that breaks down to 0 buys and 12 sells. Those positions are worth an estimated $2.0M at current prices.
Historically, Prasad Suyash's trades have earned a strong insider score of 90/100 across 8 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +82.5%.
The biggest single holding is TSHA (~$2.0M) as CMO And Head Of R&D. The recent filings there lean toward selling, a net 142,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2022 | TSHA Taysha Gene Therapies, Inc. | CMO And Head Of R&D | Sell | 12,861 | $3.70 | $47,649.79 | -2.4% | -45.5% | -82.5% | |
| Jul 1, 2022 | TSHA Taysha Gene Therapies, Inc. | CMO And Head Of R&D | Sell | 50,139 | $3.65 | $183,080.87 | -8.4% | -41.4% | -80.8% | |
| Jul 1, 2021 | TSHA Taysha Gene Therapies, Inc. | CMO And Head Of R&D | Sell | 79,000 | $22.63 | $1,787,935.64 | -11.7% | -8.9% | -83.6% |